Glymphatic system dysfunction in gliomas: A systematic review and meta-analysis of DTI-ALPS index.

J NeuroradiolJun 5, 2026 (epub)
Clinical ResearchNeurologyOncology (Medical)

Fatemeh Taheri Dehaghi, Amirsaman Soleimani Nasab, Narges Arabi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the DTI-ALPS index in adults with histologically confirmed gliomas to assess glymphatic system dysfunction. The analysis included 14 studies and found that high-grade gliomas had lower ALPS indices compared to low-grade tumors (MD=0.14, 95% CI: 0.11-0.16). Additionally, lower ALPS indices were associated with worse overall survival (HR=0.73, 95% CI: 0.49-1.10).

Key findings

  • High-grade gliomas exhibited lower ALPS indices than low-grade tumors (MD=0.14, 95% CI: 0.11-0.16).
  • IDH wild-type gliomas showed lower ALPS indices than IDH-mutant tumors (MD=0.14, 95% CI: 0.10-0.18).
  • Lower ALPS index is associated with worse overall survival (HR=0.73, 95% CI: 0.49-1.10).

Why it matters

Understanding glymphatic dysfunction in gliomas can enhance diagnostic and prognostic capabilities, potentially guiding treatment decisions and patient management strategies in clinical practice.

What to keep in mind

The study identified a very high risk of bias in 14% of included studies and some concerns in 64%.

Source

PubMed · PMID 42247804

Published in J Neuroradiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.